China

Market Access

Chinese flag atop pills on black background

Is the next generation of Chinese biotech ready to go global...

Will Chinese biotechs continue to transfer most ex-China rights, or retain their strongest assets and compete internationally themselves?

Oncology

Australia, CAR-T therapy, and solid tumours

Bev Menner, chief executive officer at Cell Therapies Pty Ltd, discusses CAR-T therapies for solid tumours and Australian and APAC R&D more generally.

News

InnoCare and Eli Lilly logos over a handshake graphic in the background

Lilly forges $3.35bn alliance with China's InnoCare

Eli Lilly continues a busy period of deal-making with a five-project partnership with InnoCare that includes $100m in upfront and near-term payments.

News

Hengrui gets world-first okay for platelet drug hetrombopag

Hengrui's oral TPO agonist, hetrombopag, is the first in the class to be approved for thrombocytopenia caused by chemotherapy for solid tumours.

News

Akeso and CStone secure China clearances for next-generation...

Hong Kong biopharma company Akeso has secured clinical trial clearance in China for a next-generation antibody-drug conjugate (ADC) targeting B7-H3.

News

Sandoz adds 10 biosimilars through $322m Henlius deal

Sandoz is set to add up to 10 new biosimilar assets to its portfolio under a new collaboration deal with China’s Shanghai Henlius Biotech.

Is the next generation of Chinese biotech ready to go global...

Australia, CAR-T therapy, and solid tumours

Lilly forges $3.35bn alliance with China's InnoCare

Hengrui gets world-first okay for platelet drug hetrombopag

Akeso and CStone secure China clearances for next-generation...

Sandoz adds 10 biosimilars through $322m Henlius deal

argenx's Forte acquisition delivers coeliac trial win

Discover a new era of healthcare panel engagement: Grounded ...

China

Editor's Picks